Author

A. T. Mayer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell-cell communication· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

A. J. Ritchie· 1 shared A. K. Grosskopf· 1 shared C. L. Maikawa· 1 shared C. Liong· 1 shared E. A. Collisson· 1 shared E. Appel· 1 shared E. C. Gale· 1 shared E. L. Meany· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. J. Ritchie

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Injectable Nanoparticle-Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies

S. Correa, E. C. Gale, A. T. Mayer, Z. Xiao, C. Liong, J. H. Klich, R. A. Brown, E. L. Meany, O. M. Saouaf, C. L. Maikawa, A. K. Grosskopf, J. L. Mann, J. Idoyaga, E. Appel

This paper develops injectable hydrogels to safely deliver CD40 agonist antibodies, reducing toxicity while maintaining anti-cancer efficacy in a melanoma model.

bioRxiv · Jun 27, 2021Bioengineering

Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma Using Autophagy Inhibition, MEK blockade and CD40 Agonism

H. Jiang, T. Courau, L. Lupin-Jimenez, J. Borison, A. J. Ritchie, A. T. Mayer, M. F. Krummel, E. A. Collisson

This study shows that combining MEK inhibition, autophagy inhibition, and CD40 agonism activates the Type I Interferon/STING pathway in PDA tumors, reprograms TAMs, and enhances anti-tumor immunity in a mouse model.

bioRxiv · Nov 5, 2020 · PreprintCancer Biology